Alpha 1 Lung Disease Market, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, By Region

Description

Alpha 1 Lung Disease Market is estimated to be valued at USD 7.05 Bn in 2025 and is expected to reach USD 23.68 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 7.05 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	18.90%	2032 Value Projection:	USD 23.68 Bn

Alpha 1 Lung Disease is a rare genetic disorder that affects the lungs and liver. It is caused by a deficiency of alpha-1 antitrypsin (AAT), a protein that helps protect the lungs from damage. This condition leads to the development of chronic obstructive pulmonary disease (COPD) and liver disease.

The global Alpha 1 Lung Disease market is driven by the increasing prevalence of the disease, growing awareness among healthcare professionals, and advancements in diagnostic techniques. According to the Alpha-1 Foundation, it is estimated that around 100,000 individuals in the U.S. and Europe have been diagnosed with Alpha 1 Lung Disease. However, the actual number of affected individuals is believed to be much higher.

Market Dynamics:

The market for Alpha 1 Lung Disease is primarily driven by the rising prevalence of the disease. As more individuals are being diagnosed with Alpha 1 Lung Disease, the demand for effective treatment options is increasing. This has led to a surge in research and development activities by key players in the market.

However, there are certain factors that restrain the growth of the market. Limited awareness about the disease among the general population and healthcare professionals hinders early diagnosis and treatment. Additionally, the high cost of treatment and lack of reimbursement policies in some regions pose challenges to market growth.

Despite these challenges, the market presents several opportunities for growth. Technological advancements in diagnostic techniques, such as genetic testing, are expected to improve early detection rates. Moreover, the development of novel therapies and targeted drugs holds promise for the treatment of Alpha 1 Lung Disease.

For instance, in June 2022, U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), the Center within the U.S. Food and Drug Administration (FDA) are pleased to announce their partnership with the Critical Path Institute (C-Path), a non-profit organization to initiate planning for a consortium aimed at developing tools appropriate for use in clinical development programs for alpha-1 antitrypsin deficiency (AATD), a rare disease causing progressive destruction of lung tissue leading to premature mortality or need for lung transplant.

Key Features of the Study:

This report provides an in-depth analysis of the global Alpha 1 Lung Disease market, including market size (US$ Bn) and Compound Annual Growth Rate (CAGR %) for the forecast period 2025-2032
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
The key companies covered as a part of this study include AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited., CSL Behring, Vertex Pharmaceuticals Incorporated, Amgen Inc., Sanofi, GSK plc, Gilead Sciences, Inc., AbbVie Inc., and Regeneron Pharmaceuticals Inc.
Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics
The global Alpha 1 Lung Disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alpha 1 Lung Disease market

Alpha 1 Lung Disease Market Segmentation:

By Disease Type
- Alpha-1 Antitrypsin Deficiency
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Fibrosis
- Bronchiectasis
- Others
By Treatment Type
- Augmentation Therapy
- Bronchodilators
- Corticosteroids
- Oxygen Therapy
- Lung Transplantation
- Others
By Route of Administration
- Injectable
- Oral
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- AstraZeneca
- Boehringer Ingelheim International GmbH
- F.Hoffmann-La Roche Ltd
- Novartis AG
- Pfizer Inc.
- Merck & Co., Inc.,
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company Limited.
- CSL Behring
- Vertex Pharmaceuticals Incorporated
- Amgen Inc.
- Sanofi
- GSK plc
- Gilead Sciences, Inc.
- AbbVie Inc.
- Regeneron Pharmaceuticals Inc.

Product Code: CMI6188

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Alpha 1 Lung Disease, By Disease Type
- Market Alpha 1 Lung Disease, By Treatment Type
- Market Alpha 1 Lung Disease, By Route of Administration
- Market Alpha 1 Lung Disease, By Distribution Channel
- Market Alpha 1 Lung Disease, By Region
Coherent Opportunity Map (COaM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising Prevalence of COPD Globally
Increasing Diagnosis Rates
New Product Launches
Strong Pipeline of Drugs
- Restraints
Limited awareness about the disease among the general population
- Opportunities
Technological advancements in diagnostic techniques
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Alpha 1 Lung Disease Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Alpha 1 Lung Disease Market, By Disease Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Alpha-1 Antitrypsin Deficiency
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Chronic Obstructive Pulmonary Disease (COPD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Pulmonary Fibrosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Bronchiectasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Alpha 1 Lung Disease Market, By Treatment Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Augmentation Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Oxygen Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Lung Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

7. Alpha 1 Lung Disease Market, By Route of Administration, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

8. Alpha 1 Lung Disease Market, By Distribution Channel, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

9. Alpha 1 Lung Disease Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021-2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
CSL Behring
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Vertex Pharmaceuticals Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
GSK plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Regeneron Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views

11. Section

Research Methodology
About us